INTERNAL DOSIMETRY IN NUCLEAR MEDICINE
DOI:
https://doi.org/10.15392/bjrs.v1i1.9Keywords:
Internal Dosimetry, Dose Calculations, Nuclear MedicineAbstract
This article reviews the current state of the art in the calculation of radiation doses for radiopharmaceuticals. Basics of dose calculations are briefly reviewed, and the sources of input data for the calculations are reviewed. Although dose calculations are needed for all kinds of radiopharmaceuticals, dose calculations in therapeutic applications are the most important for the patient; the status of dose calculations for most important therapeutic uses of radiopharmaceuticals is discussed, and the importance of performing patient-individualized dose calculations is emphasized- Views: 513
- PDF Downloads: 412
Downloads
References
Marinelli L, Quimby E, Hine G: Dosage determination with radioactive isotopes II, practical considerations in therapy and protection, Am J Roent Radium Ther 59:260-280, 1948.
Quimby E and Feitelberg S: Radioactive isotopes in medicine and biology, Philadelphia, 1963, Lea and Febiger.
Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm. Feb;18(1):89-97, 2003.
Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. Jan;40 (2):207-12, 2013.
Stabin MG,Siegel JA. Physical Models and Dose Factors for Use in Internal Dose Assessment. Health Physics, 85 (3):294-310, 2003.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The Second-Generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine. J Nucl Med 46 1023-1027, 2005.
Cristy M. and Eckerman K. Specific absorbed fractions of energy at various ages from internal photons sources. ORNL/TM-8381 V1-V7. Oak Ridge National Laboratory, Oak Ridge, TN, 1987.
Stabin M, Watson E, Cristy M, Ryman J, Eckerman K, Davis J, Marshall D., Gehlen K. Mathematical models and specific absorbed fractions of photon energy in the nonpregnant adult female and at the end of each trimester of pregnancy. ORNL Report ORNL/TM-12907, 1995.
Stabin MG, Xu XG, Emmons MA, Segars WP, Shi C, Fernald MJ. RADAR Reference Adult, Pediatric, and Pregnant Female Phantom Series for Internal and External Dosimetry, J Nucl Med 253:1807–1813, 2013.
Stabin MG. Fundamentals of Nuclear Medicine Dosimetry. Springer, New York, NY, February 2008.
Siegel J, Thomas S, Stubbs J, Stabin M, Hays M, Koral K, Robertson J, Howell R, Wessels B, Fisher D, Weber D, Brill A. MIRD Pamphlet No 16 – Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for Use in Human Radiation Dose Estimates. J Nucl Med 40:37S-61S, 1999.
International Commission on Radiological Protection. Radiation Dose Estimates for Radiopharmaceuticals. ICRP Publications 53, 80, and 106, with addenda. Pergammon Press, 1983-2008.
International Commission on Radiological Protection. Recommendations of the ICRP. ICRP Publication 103, Annals of the ICRP 37 (2-3) 2007.
Eschmann, S. M., Reischl, G., Bilger, K., Kupferschlager, J., Thelen, M. H., Dohmen, B. M., Besenfelder, H., & Bares, R. "Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET", European Journal of Nuclear Medicine and Molecular Imaging, vol. 29, no. 6, pp. 760-767, 2002.
Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G, Volterrani D, Chiacchio S, AlSharif A, Borso E, Raschilla R, Di Martino F, Mariani G. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism. Cancer Biotherapy And Radiopharmaceuticals. 20(2) 218-223, 2005.
Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, Schicha H. Graves’ disease and radioiodine therapy: Is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin, 47 1: 13-17, 2008.
Stabin MG, Flux GD. Internal dosimetry as a tool for radiation protection of the patient in nuclear medicine. Review article, Biomedical Imaging and Intervention Journal, 3(2):e28, 2007.
Furhang E. E., Larson S. M., Buranapong P., & Humm J. L. "Thyroid cancer dosimetry using clearance fitting", Journal of Nuclear Medicine, vol. 40, no. 1, pp. 131-136, 1999.
Maxon H. R., Thomas S. R., & Samaratunga R. C. "Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer", Thyroid, vol. 7, no. 2, pp. 183-187, 1997.
Hoefnagel C. A. "Nuclear medicine therapy of neuroblastoma", Quarterly Journal of Nuclear Medicine, vol. 43, no. 4, pp. 336-343, 1999.
Matthay K. K., Panina C., Huberty J., Price D., Glidden D. V., Tang H. R., Hawkins R. A., Veatch J., & Hasegawa B. "Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma. treated with I-131-MIBG", Journal of Nuclear Medicine, vol. 42, no. 11, pp. 1713-1721, 2001.
Gaze M. N., Chang Y. C., Flux G. D., Mairs R. J., Saran F. H., & Meller S. T. "Feasibility of dosimetry-based high-dose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma", Cancer Biotherapy and Radiopharmaceuticals, vol. 20, no. 2, pp. 195-199, 2005.
Monsieurs M., Brans B., Bacher K., Dierckx R., & Thierens H. "Patient dosimetry for I-131-MIBG therapy for neuroendocrine tumours based on I-123-MIBG scans", European Journal of Nuclear Medicine and Molecular Imaging, vol. 29, no. 12, pp. 1581-1587, 2002.
Flux G. D., Guy M. J., Papavasileiou P., South C., Chittenden S. J., Flower M. A., & Meller S. T. "Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG", Cancer Biotherapy and Radiopharmaceuticals, vol. 18, no. 1, pp. 81-87, 2003.
Wahl R. L., Kroll S., & Zasadny K. R. "Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation", Journal of Nuclear Medicine, vol. 39, no. 8, pp. 14S-20S, 1998.
Wiseman G. A., White C. A., Sparks R. B., Erwin W. D., Podoloff D. A., Lamonica D., Bartlett N. L., Parker J. A., Dunn W. L., Spies S. M., Belanger R., Witzig T. E., & Leigh B. R. "Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin (TM) radioimmunotherapy for low-grade, follicular, or transformed B- cell non-Hodgkin's lymphoma", Critical Reviews in Oncology Hematology, vol. 39, no. 1-2, pp. 181-194, 2001.
Hindorf C, Flux G, Lewington V, Aksnes AK, Harris P, Parker C. A biodistribution and dosimetry study of therapeutic 223Ra-chloride (Alpharadin) in patients with osteoblastic skeletal metastases secondary to hormone refractory prostate cancer. J Nucl Med. 49 (Supplement 1):145P, 2008.
Barone R., Walrand S., Valkema R., Kvols L., Smith C., Krenning E. P., Jamar F., & Pauwels S. "Correlation between acute red marrow (RM) toxicity and RM exposure during Y-90-SMT487 therapy", Journal of Nuclear Medicine, vol. 43, no. 5, p. 1267, 2002.
Hindorf, C., Chittenden, S., Causer, L., Lewington, V. J., Macke, H. R., Flux, G. D Dosimetry for Y-90-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm, 22 (1):130-135, 2007.
Forrer F, Uusijärvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, Maecke. HR. A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31:1257–1262, 2004.
Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, Baio SM, Sansovini M,. Paganelli G. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 35:1847–1856, 2008.
Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, Pauwels S. Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose–Effect Relationship. J Nucl Med 46:99S–106S, 2005.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
